Initial therapy in multiple myeloma: investigating the new treatment paradigm
Kettle et al.
J Oncol Pharm Pract 2009;15:131-141.
ABSTRACT
Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial
Hulin et al.
JCO 2009;27:3664-3670.
ABSTRACT
| FULL TEXT
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel et al.
NEJM 2008;359:906-917.
ABSTRACT
| FULL TEXT
First thalidomide clinical trial in multiple myeloma: a decade
van Rhee et al.
Blood 2008;112:1035-1038.
ABSTRACT
| FULL TEXT
Multiple myeloma
Kyle and Rajkumar
Blood 2008;111:2962-2972.
ABSTRACT
| FULL TEXT
Patterns of Survival in Multiple Myeloma: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2003
Kristinsson et al.
JCO 2007;25:1993-1999.
ABSTRACT
| FULL TEXT
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study
Mateos et al.
Blood 2006;108:2165-2172.
ABSTRACT
| FULL TEXT
Myeloma - new approaches to combined nephrological-haematological management
Haubitz and Peest
Nephrol Dial Transplant 2006;21:582-590.
FULL TEXT
Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy
Facon et al.
Blood 2006;107:1292-1298.
ABSTRACT
| FULL TEXT
Weekly Cyclophosphamide and Alternate-Day Prednisone: An Effective, Convenient, and Well-Tolerated Oral Treatment for Relapsed Multiple Myeloma After Autologous Stem Cell Transplantation
Trieu et al.
Mayo Clin Proc. 2005;80:1578-1582.
ABSTRACT
Thalidomide With Continuous Low-Dose Dexamethasone for Multiple Myeloma
Gardyn
JCO 2005;23:1323-1323.
FULL TEXT
Treatment of multiple myeloma
Barlogie et al.
Blood 2004;103:20-32.
ABSTRACT
| FULL TEXT
Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma
Dimopoulos et al.
Ann Oncol 2003;14:1039-1044.
ABSTRACT
| FULL TEXT
Clinical and pharmacokinetic phase II study of fotemustine in refractory and relapsing multiple myeloma patients
Dumontet et al.
Ann Oncol 2003;14:615-622.
ABSTRACT
| FULL TEXT
Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study
Segeren et al.
Blood 2003;101:2144-2151.
ABSTRACT
| FULL TEXT
Effects of Long-Term Intravenous Ibandronate Therapy on Skeletal-Related Events, Survival, and Bone Resorption Markers in Patients With Advanced Multiple Myeloma
Menssen et al.
JCO 2002;20:2353-2359.
ABSTRACT
| FULL TEXT
Bone Marrow Transplantation in Patients with Multiple Myeloma: Prognostic Significance of MR Imaging
Lecouvet et al.
Am. J. Roentgenol. 2001;176:91-96.
ABSTRACT
| FULL TEXT
Treatment of myeloma
Smith and Newland
QJM 1999;92:11-14.
FULL TEXT
Lung-Resistance-Related Protein Expression Is a Negative Predictive Factor for Response to Conventional Low but not to Intensified Dose Alkylating Chemotherapy in Multiple Myeloma
Raaijmakers et al.
Blood 1998;91:1029-1036.
ABSTRACT
| FULL TEXT
A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma
Attal et al.
NEJM 1996;335:91-97.
ABSTRACT
| FULL TEXT
The Treatment of Multiple Myeloma
Alexanian and Dimopoulos
NEJM 1994;330:484-489.
FULL TEXT
Biphasic Pattern of Bacterial Infection in Multiple Myeloma
SAVAGE et al.
ANN INTERN MED 1982;96:47-50.
ABSTRACT
Therapy of Primary Amyloidosis With Melphalan and Prednisone
Schwartz et al.
Arch Intern Med 1979;139:1144-1147.
ABSTRACT
Amyloidosis With Plasma Cell Dyscrasia: An Overlooked Cause of Adult Onset Sensorimotor Neuropathy
Trotter et al.
Arch Neurol 1977;34:209-214.
ABSTRACT
Acute Leukemia in Multiple Myeloma
GONZALEZ et al.
ANN INTERN MED 1977;86:440-443.
ABSTRACT
Carcinoma of the Breast: Occurrence After Treatment With Melphalan for Multiple Myeloma
Bell et al.
JAMA 1976;236:1609-1610.
ABSTRACT
Changes in Lymphocyte Surface Immunoglobulins in Myeloma and the Effect of an RNA-Containing Plasma Factor
CHEN et al.
ANN INTERN MED 1975;83:625-631.
ABSTRACT
Resolution of Primary Amyloidosis During Chemotherapy: Studies in a Patient with Nephrotic Syndrome
COHEN et al.
ANN INTERN MED 1975;82:466-473.
ABSTRACT
IgD Multiple Myeloma: Review of 133 Cases
Jancelewicz et al.
Arch Intern Med 1975;135:87-93.
ABSTRACT
Cellular Kinetics in Multiple Myeloma: A New Approach to Staging and Treatment
Salmon and Durie
Arch Intern Med 1975;135:131-138.
ABSTRACT
Remission Maintenance Therapy for Multiple Myeloma
Southwest Oncology Group Study
Arch Intern Med 1975;135:147-152.
ABSTRACT
Treatment of Myeloma: Comparison of Melphalan, Chlorambucil, and Azathioprine
Southeastern Cancer Study Group
Arch Intern Med 1975;135:157-162.
ABSTRACT
Treatment of Plasma Cell Myeloma With Cytotoxic Agents
Bergsagel and Pruzanski
Arch Intern Med 1975;135:172-176.
ABSTRACT
Combination Chemotherapy in Advanced Hodgkin's Disease: Induction and Maintenance of Remission
FREI et al.
ANN INTERN MED 1973;79:376-382.
ABSTRACT
Hemodialysis in Myelomatosis
LOCK et al.
ANN INTERN MED 1973;78:454-454.
ABSTRACT
Comment: The Non-Hodgkin's Lymphomas
Rubin
JAMA 1973;223:175-178.
ABSTRACT
Bone Healing in Multiple Myeloma with Melphalan Chemotherapy
RODRIGUEZ et al.
ANN INTERN MED 1972;76:551-556.
ABSTRACT
Melphalan and Myeloma: Experience with a Low-Dose Continuous Regimen
MCARTHUR et al.
ANN INTERN MED 1970;72:665-670.
ABSTRACT
Bence Jones proteins, azotemia was more frequent, the incidence of response was low, and survival was short. Median survival for patients treated with melphalan-prednisone was about six months longer than the survival of patients treated with melphalan alone. Results support the use of intermittent courses of concurrent chemotherapy with large doses of melphalan and prednisone in patients with multiple myeloma.